BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 31571207)

  • 1. The evolving role of next generation sequencing in myelodysplastic syndromes.
    Spaulding TP; Stockton SS; Savona MR
    Br J Haematol; 2020 Jan; 188(2):224-239. PubMed ID: 31571207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
    Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
    Abdulbaki R; Pullarkat ST
    Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome.
    Hughes CFM; Gallipoli P; Agarwal R
    Pathology; 2021 Apr; 53(3):328-338. PubMed ID: 33676768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Noy-Lotan S; Krasnov T; Dgany O; Jeison M; Yanir AD; Gilad O; Toledano H; Barzilai-Birenboim S; Yacobovich J; Izraeli S; Tamary H; Steinberg-Shemer O
    Br J Haematol; 2021 May; 193(3):570-580. PubMed ID: 33368157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
    Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
    Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of next-generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome.
    Kawata E; Lazo-Langner A; Xenocostas A; Hsia CC; Howson-Jan K; Deotare U; Saini L; Yang P; Broadbent R; Levy M; Howlett C; Stuart A; Kerkhof J; Santos S; Lin H; Sadikovic B; Chin-Yee I
    Br J Haematol; 2021 Feb; 192(4):729-736. PubMed ID: 32588428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Dawn of next generation DNA sequencing in myelodysplastic syndromes- experience from Pakistan.
    Anwar N; Memon FA; Shahid S; Shakeel M; Irfan M; Arshad A; Naz A; Ujjan ID; Shamsi T
    BMC Genomics; 2021 Dec; 22(1):903. PubMed ID: 34915860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation.
    Nassereddine S; Nishihori T; Padron E; Mahfouz R; Bazarbachi A; Komrokji RS; Kharfan-Dabaja MA
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):7-13. PubMed ID: 27771290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
    Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
    J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
    Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
    BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of myelodysplastic syndrome in the era of next-generation sequencing.
    Tobiasson M; Kittang AO
    J Intern Med; 2019 Jul; 286(1):41-62. PubMed ID: 30869816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
    Palomo L; Ibáñez M; Abáigar M; Vázquez I; Álvarez S; Cabezón M; Tazón-Vega B; Rapado I; Fuster-Tormo F; Cervera J; Benito R; Larrayoz MJ; Cigudosa JC; Zamora L; Valcárcel D; Cedena MT; Acha P; Hernández-Sánchez JM; Fernández-Mercado M; Sanz G; Hernández-Rivas JM; Calasanz MJ; Solé F; Such E;
    Br J Haematol; 2020 Mar; 188(5):605-622. PubMed ID: 31621063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
    Kohlmann A; Bacher U; Schnittger S; Haferlach T
    Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Getting personal with myelodysplastic syndromes: is now the right time?
    Chokr N; Pine AB; Bewersdorf JP; Shallis RM; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Apr; 12(4):215-224. PubMed ID: 30977414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.
    Ferrone CK; McNaughton AJM; Rashedi I; Ring B; Buckstein R; Tsui H; Rauh MJ
    Mod Pathol; 2023 Mar; 36(3):100068. PubMed ID: 36788103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Generation Gene Sequencing Differentiates Hypoplastic Myelodysplastic Syndrome from Aplastic Anemia.
    Lew JL; Fenderson JL; Carmichael MG
    Hawaii J Med Public Health; 2017 Nov; 76(11 Suppl 2):10-12. PubMed ID: 29164009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of Next Generation Sequencing for AML/MDS Diagnosis and Treatment].
    Cheng HC; Liu SW; Liu Y; Zhao XF; Li W; Qiu L; Ma J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1631-1635. PubMed ID: 29262888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.